

# This Week's **Top** Industry News

Provided as a service to DCAT member companies each Friday.

**BUSY WEEK?** Here are the **TOP INDUSTRY NEWS** stories you might have missed, as selected by DCAT Editorial Director *Patricia Van Arnum*.

**1. [Baxalta and Shire Agree to Merge in \\$32 Billion Deal](#)**

The boards of directors of Shire and Baxalta, the biopharmaceutical company spun off from Baxter in 2015, have reached an agreement under which Shire will combine with Baxalta in a deal valued at approximately \$32 billion, creating a specialty biopharmaceutical company with a strong rare-disease focus. Shire had previously made a \$30 billion bid to acquire Baxalta in August 2015. [Read More](#)

**2. [Merck Settles Vioxx Class Action Lawsuit for \\$830 Million](#)**

Merck & Co. Inc., has settled a previously disclosed securities class action lawsuit for \$830 million for Vioxx (rofecoxib), a nonsteroidal anti-inflammatory drug that was withdrawn from the market in 2004 due to safety concerns. [Read More](#)

**3. [FDA Posts Warning Letter to Hisun for Data Issues](#)**

The US Food and Drug Administration (FDA) has posted a Warning Letter on its website to Zhejiang Hisun Pharmaceutical Co., Ltd., a Chinese pharmaceutical company, for GMP violations relating to data integrity at the company's drug manufacturing facility in Taizhou City, Zhejiang Province, China. [Read More](#)

**4. [Sanofi Signs Potential \\$750 Million-Plus Pact with Warp Drive Bio](#)**

Sanofi and Warp Drive Bio, a privately held biotechnology company, have extended and reshaped their existing collaboration to discover oncology therapeutics and antibiotics in a deal valued at more than \$750 million. [Read More](#)

**5. [Sanofi, Innate Pharma Sign \\$434 Million Bispecific Antibody Pact](#)**

Sanofi and Innate Pharma, a Marseille, France-based biopharmaceutical company, have entered into a research collaboration and licensing agreement to apply Innate Pharma's new proprietary technology to the development of bispecific antibodies in a deal valued up to \$434 million. [Read More](#)

**6. [Merck Acquires IOmet to Build Immuno-Oncology Position](#)**

In yet another deal in immuno-oncology, Merck & Co. has acquired IOmet, a privately held UK-based drug discovery company based in Edinburgh, Scotland, focused on developing cancer immunotherapies. [Read More](#)

**7. [J&J Forms Pact for Hepatitis B Drugs; Forms Early-Stage Collaborations](#)**

Johnson & Johnson Innovation and Janssen Pharmaceuticals have formed an exclusive license agreement with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. a Chinese domestic pharmaceutical company, to develop, manufacture, and commercialize, outside of China, treatments for chronic hepatitis B. In separate news, J&J also announced 21 early-stage collaborations. [Read More](#)

## 8. [Pfizer Invests in Four Early-Stage Companies](#)

Pfizer has expanded its R&D investment strategy to include early-stage companies to provide both equity and access to resources. The first four investments include \$46 million in financing to companies for conditionally active biologics, immuno-oncology, neurodegenerative technologies, and gene therapy. [Read More](#)

## 9. [Catalent, Roche Sign \\$600 Million-Plus Pact for ADC Technology](#)

Roche and Catalent have signed a research collaboration for Catalent's SmartTag technology, an antibody drug conjugate (ADC) platform. For Catalent, the deal includes an up-front \$1 million fee, additional research funding, and a potential of \$618 million in development and commercial milestones and royalties. [Read More](#)

## 10. [Thermo Fisher to Acquire Affymetrix for \\$1.3 Billion](#)

Thermo Fisher Scientific Inc. has agreed to acquire Affymetrix Inc., a provider of cellular and genetic analysis products, for approximately \$1.3 billion. [Read More](#)

*The DCAT organization is happy to provide this service to its members each Friday.  
Have a great weekend!*

---

### About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691  
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599  
[www.dcat.org](http://www.dcat.org)

[Forward this email](#)



This email was sent to [esanders@dcat.org](mailto:esanders@dcat.org) by [dcatnews@dcat.org](mailto:dcatnews@dcat.org) | [Update Profile/Email Address](#) | Rapid removal with [SafeUnsubscribe™](#) | [About our service provider.](#)

Drug, Chemical, & Associated Technologies Association | One Union Street | Suite 208 | Robbinsville | NJ | 08691